Fingerprint spectrum establishment method of Xuefuzhuyu composition, standard fingerprint spectrum of Xuefuzhuyu composition and application of standard fingerprint spectrum
The fingerprint of the Xuefu Zhuyu composition generated by high-performance liquid chromatography has been solved, which cannot fully reflect the correlation between traditional Chinese medicine ingredients in the existing technology, achieved uniformity and stability control of traditional Chinese medicine quality, and improved the Xuefu Zhuyu Zhuyu. Quality control level of stasis composition.
Patent Information
- Application Number
- CN202411385588.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-30
- Publication Date
- 2024-11-15
AI Technical Summary
The existing technology lacks fingerprint mapping evaluation methods for Xuefu Zhuyu composition, and cannot fully reflect the correlation between complex Chinese medicine ingredients, resulting in uneven quality control of Chinese medicine and affecting industrial development.
After using methanol to dissolve the Xuefu Yuyu composition, high-performance liquid chromatography was performed to generate a fingerprint of the Xuefu Yuyu composition, including 8 designated peaks, representing different medicinal ingredients, and establishing a standard fingerprint map to Implement quality inspection.
By reflecting the correlation of chemical components of traditional Chinese medicine, the quality control level of Xuefu Zhuyu composition is improved, ensuring its quality uniformity and stability, and providing a more comprehensive quality detection method.
Smart Images

Figure CN118961952A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of traditional Chinese medicine quality detection methods, and in particular to a fingerprint establishment method of a Xuefu Zhuyu composition and a standard fingerprint spectrum and application thereof. Background Art
[0002] Xuefu Zhuyu Recipe originated from "Yi Lin Gaicuo" written by Wang Qingren, a doctor in the Qing Dynasty. It is a classic prescription among the prescriptions for promoting blood circulation and removing blood stasis. It has the effects of promoting blood circulation and removing blood stasis, promoting qi and relieving pain. The prescription is composed of 11 Chinese medicinal herbs including Bupleurum, Angelica, Rehmannia, Red Peony Root, Safflower, Stir-fried Peach Kernel, Stir-fried Fructus Aurantii Immaturus with Glutinous Rice Bran, Licorice, Chuanxiong, Achyranthes Bidentatae and Platycodon Grandiflorum. It is mainly used to treat chest pain caused by qi stagnation and blood stasis, long-term headache, pain like acupuncture with a fixed location, internal heat and depression, palpitations and insomnia, irritability, etc. Based on the Xuefu Zhuyu Recipe, modern pharmaceutical technology was used to develop Xuefu Zhuyu capsules, tablets, etc., which are collectively referred to as Xuefu Zhuyu composition below.
[0003] In the long-term production practice and quality control process of the Xuefu Zhuyu composition, there is a problem of relatively single control indicators. For example, the Chinese invention patent with document number CN101700304B discloses a method for detecting Xuefu Zhuyu oral liquid, which determines the content of amygdalin in the Xuefu Zhuyu composition by high performance liquid chromatography using an evaporative light scattering detector, and has good reproducibility, stability and precision, but its quality control index is single. The Chinese invention patent with document number CN102091167B provides a method for detecting the traditional Chinese medicine preparation Xuefu Zhuyu capsule, and its quality standard sets Bupleurum and Licorice as reference medicinal materials, and thin layer chromatography is used to identify whether the prescription of Xuefu Zhuyu capsule contains Bupleurum and Licorice ingredients; amygdalin, paeoniflorin and naringin are used as reference substances, and high performance liquid chromatography is used to detect the content of amygdalin, paeoniflorin and naringin in the prescription of Xuefu Zhuyu capsule, which changes the situation in which the quality of the compound is controlled by the content of a single indicator component in the original standard, and improves the controllability of the quality standard of Xuefu Zhuyu capsule, but this method needs to be detected by combining thin layer chromatography and high performance liquid chromatography, and the operation method is complicated.
[0004] The uniformity of the quality of Chinese medicine preparations has always been a roadblock to Chinese medicine going global. How to reasonably, scientifically and efficiently achieve the uniformity of Chinese medicine is an important issue in promoting the high-quality development of the Chinese medicine industry. The problem of uniformity of the quality of Chinese medicine needs to be solved urgently. At present, there is no perfect quality control method for the Xuefu Zhuyu composition. It is urgent to establish a multi-index component content determination and evaluation method for this product to reflect the influence of the prescription taste and production process on the product quality from a quantitative perspective, and then strengthen the production process and quality control. Summary of the invention
[0005] The present invention aims to provide a method for establishing a fingerprint of a Xuefu Zhuyu composition to solve the problems existing in the prior art: namely, the prior art lacks a fingerprint evaluation method for the Xuefu Zhuyu composition and cannot comprehensively reflect the correlation between complex Chinese medicine components.
[0006] In order to achieve the above object, the present invention adopts the following technical scheme:
[0007] A method for establishing a fingerprint spectrum of a Xuefu Zhuyu composition comprises the following steps performed in sequence:
[0008] S1: using methanol to dissolve the Xuefu Zhuyu composition, and obtaining a test solution after ultrasonic treatment and filtration;
[0009] S2: performing high performance liquid chromatography on the test sample solution to obtain a chromatogram of the test sample; integrating the chromatograms of several test samples to generate a fingerprint of the Xuefu Zhuyu composition.
[0010] The present invention also provides a standard fingerprint of a Xuefu Zhuyu composition obtained by a method for establishing a fingerprint of the Xuefu Zhuyu composition.
[0011] The present invention also provides application of the standard fingerprint spectrum of the Xuefu Zhuyu composition in quality detection of medicines containing the Xuefu Zhuyu composition.
[0012] Further, in S2, the fingerprint spectrum includes 8 designated peaks, the first designated peak represents rehmannoside D, the second designated peak represents amygdalin, the third designated peak represents paeoniflorin, the fourth designated peak represents liquiritigenin, the fifth designated peak represents ferulic acid, the sixth designated peak represents naringin, the seventh designated peak represents hesperidin, and the eighth designated peak represents neohesperidin.
[0013] Preferably, in S2, the fingerprint spectrum includes 8 designated peaks that appear sequentially during the analysis process, including:
[0014] The first designated peak represents rehmannoside D, which is mainly derived from the medicinal raw material Rehmannia glutinosa;
[0015] The second designated peak represents amygdalin, which is mainly derived from the medicinal raw material peach kernel;
[0016] The third designated peak represents paeoniflorin, which is mainly derived from the medicinal raw material red peony root;
[0017] The fourth designated peak represents liquiritin, which is mainly derived from the medicinal raw material licorice;
[0018] The fifth designated peak represents ferulic acid, which is mainly derived from the medicinal raw materials Angelica sinensis and Ligusticum chuanxiong;
[0019] The sixth designated peak represents naringin, which is mainly derived from the medicinal raw material Fructus Aurantii Immaturus;
[0020] The seventh designated peak represents hesperidin, which is mainly derived from the medicinal raw material Fructus Aurantii Immaturus;
[0021] The 8th designated peak represents neohesperidin, which is mainly derived from the medicinal raw material Fructus Aurantii Immaturus.
[0022] Preferably, in S2, the fingerprint spectrum includes 8 designated peaks that appear in sequence, the first designated peak represents rehmannoside D, and its relative retention time is 0.24±10%; the second designated peak represents amygdalin, and its relative retention time is 0.52±10%; the third designated peak represents paeoniflorin, and its relative retention time is 0.64±10%; the fourth designated peak represents liquiritin, and its relative retention time is 0.79±10%; the fifth designated peak represents ferulic acid, and its relative retention time is 0.82±10%; the sixth designated peak represents naringin, and its relative retention time is 1.00; the seventh designated peak represents hesperidin, and its relative retention time is 1.04±10%; the eighth designated peak represents neohesperidin, and its relative retention time is 1.13±10%.
[0023] More preferably, in S2, the fingerprint spectrum includes 8 designated peaks that appear in sequence, the first designated peak represents rehmannoside D, and its relative retention time is 0.24±5%; the second designated peak represents amygdalin, and its relative retention time is 0.52±5%; the third designated peak represents paeoniflorin, and its relative retention time is 0.64±5%; the fourth designated peak represents liquiritin, and its relative retention time is 0.79±5%; the fifth designated peak represents ferulic acid, and its relative retention time is 0.82±5%; the sixth designated peak represents naringin, and its relative retention time is 1.00; the seventh designated peak represents hesperidin, and its relative retention time is 1.04±5%; the eighth designated peak represents neohesperidin, and its relative retention time is 1.13±5%.
[0024] Most preferably, in S2, the fingerprint spectrum includes 8 designated peaks appearing in sequence, the first designated peak represents rehmannoside D, and its relative retention time is 0.24±2%; the second designated peak represents amygdalin, and its relative retention time is 0.52±2%; the third designated peak represents paeoniflorin, and its relative retention time is 0.64±2%; the fourth designated peak represents liquiritin, and its relative retention time is 0.79±2%; the fifth designated peak represents ferulic acid, and its relative retention time is 0.82±2%; the sixth designated peak represents naringin, and its relative retention time is 1.00; the seventh designated peak represents hesperidin, and its relative retention time is 1.04±2%; the eighth designated peak represents neohesperidin, and its relative retention time is 1.13±2%.
[0025] The detection result of the retention time is ±10% of the above average relative retention time (the variation range is within ±10% of the standard value, or within ±5%, or within ±2%), and the above chromatographic peak can be determined to be the corresponding designated peak.
[0026] Further, in S2, the conditions for high performance liquid chromatography detection are:
[0027] Chromatographic column: octadecyl bonded silica gel chromatographic column;
[0028] Mobile phase: acetonitrile as mobile phase A, 0.1% phosphoric acid aqueous solution as mobile phase B; gradient elution was used;
[0029] Flow rate: 0.8~1.2mL / min;
[0030] Column temperature: 25-35°C;
[0031] Detection wavelength: 200~403nm;
[0032] Injection volume: 5~20μL.
[0033] Further, in S2, the elution procedure is:
[0034] 0-4min, 5%-6% mobile phase A;
[0035] 4-13 min, 6%-18% mobile phase A;
[0036] 13-18 min, 18%-19% mobile phase A;
[0037] 18-20 min, 19%-20% mobile phase A;
[0038] 20-30 min, 20%-21% mobile phase A;
[0039] 30-40 min, 21%-35% mobile phase A;
[0040] 40-50 min, 35%-50% mobile phase A.
[0041] Furthermore, in S2, the chromatographic column is a GL science C18 chromatographic column, with dimensions of 4.6×250 mm and a particle size of 5 μm.
[0042] Furthermore, in S1, the volume percentage of methanol is 50% to 100%; the Xuefu Zhuyu composition is ground and mixed with methanol, and the usage ratio of the Xuefu Zhuyu composition to methanol is 0.5 g:50 mL.
[0043] Furthermore, in S1, the parameter conditions of the ultrasonic treatment are: power 100-300 W, frequency 25-100 kHz, time 20-60 minutes; the pore size of the microporous filter membrane used for filtration is 0.45 μm.
[0044] Preferably, in S1, the parameter conditions of ultrasonic treatment are: power 300 W, frequency 40 kHz, and time 40 minutes.
[0045] Furthermore, in parts by weight, the raw materials of the Xuefu Zhuyu composition include: 25-30 parts of bupleurum, 75-90 parts of angelica, 75-90 parts of rehmannia, 50-60 parts of red peony root, 75-90 parts of safflower, 105-120 parts of peach kernel, 50-60 parts of Citrus aurantium, 25-30 parts of licorice, 35-45 parts of chuanxiong, 75-90 parts of Achyranthes bidentata, and 35-45 parts of Platycodon.
[0046] More preferably, in parts by weight, the raw materials of the Xuefu Zhuyu composition include: 29.9 parts of bupleurum, 89.8 parts of angelica, 89.9 parts of rehmannia, 59.9 parts of red peony root, 89.9 parts of safflower, 119.8 parts of peach kernel, 59.9 parts of Citrus aurantium, 29.9 parts of liquorice, 44.9 parts of ligusticum, 89.9 parts of Achyranthes bidentata and 44.9 parts of Platycodon.
[0047] Preferably, the peach kernel is fried peach kernel, and the Citrus aurantium is fried Citrus aurantium with bran.
[0048] The principle and beneficial effects of this scheme are:
[0049] This technical solution establishes a fingerprint evaluation method for the Xuefu Zhuyu composition, which more comprehensively reflects the correlation between complex Chinese medicine ingredients, and by reflecting certain important characteristic information in the chemical components of Chinese medicine, controls the quality of Chinese medicine to ensure its uniformity and stability, thereby improving the quality control level of this variety. In response to the problems existing in quality control indicators, this technical solution selects effective / active ingredients, toxic ingredients, and index ingredients contained in the main drug as content determination indicators, and considers the correlation between content determination indicators and process stability, and establishes multi-component or multi-component content determination methods as much as possible. This solution ultimately establishes the fingerprint of this product, which more comprehensively reflects the correlation between complex Chinese medicine ingredients, and by reflecting certain important characteristic information in the chemical components of Chinese medicine, controls the quality of Chinese medicine to ensure its uniformity and stability. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1 It is the HPLC spectrum of Example 1 (A: test solution; B: mixed reference solution; 1: rehmannia glycoside D; 2: amygdalin; 3: paeoniflorin; 4: liquiritigenin; 5: ferulic acid; 6: naringin; 7: hesperidin; 8: neohesperidin).
[0051] Figure 2The chromatograms of 11 batches of samples in Example 1 are shown in FIG.
[0052] Figure 3 It is the common peak of Xuefu Zhuyu Tablets in Example 1 (S: reference peak).
[0053] Figure 4 Peak identification of the control fingerprint of Xuefu Zhuyu Tablets in Example 1 (1: rehmannoside D; 2: amygdalin; 3: paeoniflorin; 4: liquiritigenin; 5: ferulic acid; 6: naringin; 7: hesperidin; 8: neohesperidin).
[0054] Figure 5 This is the pedigree diagram of the cluster analysis of the Xuefu Zhuyu Tablets in Example 1.
[0055] Figure 6 This is a 3D scan image of the Xuefu Zhuyu Tablet in Example 2.
[0056] Figure 7 HPLC spectra of Example 2 at different column temperatures (A: column temperature 25°C; B: column temperature 30°C; C: column temperature 35°C).
[0057] Figure 8 The HPLC spectra at different flow rates of Example 2 (A: flow rate 0.8 mL / min; B: flow rate 1.0 mL / min; C: flow rate 1.2 mL / min).
[0058] Fig. 9 HPLC spectra obtained for samples treated with different extraction solvents in Example 3 (A: 50% methanol; B: 75% methanol; C: 100% methanol).
[0059] Fig.10 HPLC spectra obtained from samples treated with the extraction method of Example 3 (A: ultrasonic extraction; B: reflux extraction).
[0060] Fig.11 HPLC spectra obtained for samples treated with different extraction times in Example 3 (A: 20 minutes; B: 40 minutes; C: 60 minutes).
[0061] Fig.12 HPLC spectra obtained for different injection volumes in Example 3 (A: 5 μL; B: 10 μL; C: 15 μL; D: 20 μL).
[0062] Fig.13 The HPLC test results of the prior art of Comparative Example 1 for Xuefu Zhuyu Tablets (1: amygdalin; 2: paeoniflorin; 3: ferulic acid; 4: naringin; 5: hesperidin; 6: neohesperidin). DETAILED DESCRIPTION
[0063] The present invention is further described in detail below in conjunction with the examples, but the embodiments of the present invention are not limited thereto. Unless otherwise specified, the technical means used in the following examples and experimental examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used can be obtained from commercial sources. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art. It should be noted that the following examples all use Jinchan Zhiyang Capsules as the detection object.
[0064] Example 1: Establishment of standard characteristic spectrum
[0065] The raw materials of the Xuefu Zhuyu composition include, by weight: 25-30 parts of Bupleurum, 75-90 parts of Angelica, 75-90 parts of Rehmannia, 50-60 parts of Red Peony Root, 75-90 parts of Carthamus, 105-120 parts of Peach Kernel, 50-60 parts of Citrus Aurantium, 25-30 parts of Licorice, 35-45 parts of Chuanxiong, 75-90 parts of Achyranthes, and 35-45 parts of Platycodon. Preferably, the peach kernel is stir-fried peach kernel, and the Citrus Aurantium is stir-fried Citrus Aurantium with bran.
[0066] In this embodiment, the detection method is studied by Xuefu Zhuyu Tablets. The composition of the medicinal raw materials of the Xuefu Zhuyu Tablets is as follows: in parts by weight, the raw materials of the Xuefu Zhuyu Tablets include: 29.9 parts of Bupleurum, 89.8 parts of Angelica, 89.9 parts of Rehmannia, 59.9 parts of Red Peony Root, 89.9 parts of Carthamus, 119.8 parts of Peach Kernel, 59.9 parts of Citrus Aurantium, 29.9 parts of Licorice, 44.9 parts of Chuanxiong, 89.9 parts of Achyranthes and 44.9 parts of Platycodon; the preparation method of the Xuefu Zhuyu Tablets is carried out with reference to the SFDA standard promulgation (2010), which will not be repeated here.
[0067] (1) Main instruments, reagents, samples and standards
[0068] The instruments include: one-tenth of a microbalance (ATY224, Shimadzu Corporation, Japan), one-tenth of a microbalance (BS124S, Beijing Sartorius Scientific Instrument Co., Ltd.), high performance liquid chromatograph (LC-2030C (3D), Shimadzu Corporation, Japan), CNC ultrasonic cleaner (LQ-300DB, Kunshan Ultrasonic Instrument Co., Ltd.), digital display constant temperature water bath (HH-4, Jintan Chengxi Chunlan Experimental Instrument Factory), GL science C18 chromatographic column (4.6×250mm, 5μm, Shanghai Jier Trading Co., Ltd.).
[0069] Reagents include: methanol (2022081201, Chengdu Norshi Technology Co., Ltd.), phosphoric acid (2021060401, Chengdu Norshi Technology Co., Ltd.), and acetonitrile (2022071901, Chengdu Norshi Technology Co., Ltd.).
[0070] Standard products include: amygdalin (20221231, Beijing Solebow Technology Co., Ltd., ≥98%), paeoniflorin (C1573360, Shanghai McLean Biochemical Technology Co., Ltd., ≥98%), naringin (110702-201815, China Food and Drug Inspection Institutes, ≥98%), neohesperidin (11857-201804, China Food and Drug Inspection Institutes, ≥98%), hesperidin (110721-201818, China Food and Drug Inspection Institutes, ≥98%), ferulic acid (110773-201915, China Food and Drug Inspection Institutes, ≥98%), rehmannia glutinosa D (DSTDD010703, Chengdu Desite Biological Co., Ltd., ≥98%), and liquiritin (11610-201908, China Food and Drug Inspection Institutes, ≥98%).
[0071] Xuefu Zhuyu tablets (each tablet weighs 0.45 g, batch numbers 210903, 210904, 211101, 211102, 211003, 211004, 211104, 211105, 211006, 211201, 221101 are numbered S1 to S11 respectively)
[0072] (2) Experimental methods
[0073] (2.1) Solution preparation
[0074] (2.1.1) Preparation of test samples
[0075] Take Xuefu Zhuyu tablets, scrape off the film coating and grind them into fine powder. Take 0.5 g of powder, weigh it accurately, add 50 mL of 75% methanol (the dosage ratio of Xuefu Zhuyu composition and methanol can be (0.25 g: 50 mL) to (0.75 g: 50 mL)), weigh it, treat it with ultrasound (power 300 W, frequency 40 kHz; in actual operation, power 100-300 W, frequency 25-100 kHz) for 40 minutes (20-60 minutes in actual use), let it cool, weigh it again, make up the lost weight with 75% methanol, shake it well, filter it with a 0.45 μm microporous filter membrane, and take the filtrate to obtain it.
[0076] (2.1.2) Preparation of reference solution
[0077] Take appropriate amount of rehmannia glycoside D, amygdalin, paeoniflorin, licorice glycoside, ferulic acid, naringin, hesperidin and neohesperidin reference substances respectively, weigh accurately, add methanol solution to dissolve, and make a mixed reference substance solution containing 154.0 μg of paeoniflorin, 190.0 μg of rehmannia glycoside D, 228.0 μg of amygdalin, 52.0 μg of ferulic acid, 70.0 μg of licorice glycoside, 56.0 μg of hesperidin, 236.0 μg of naringin and 856.0 μg of neohesperidin per 1 mL.
[0078] (2.1.3) Negative sample solution
[0079] According to the prescription ratio, prepare negative samples lacking peach kernel, lacking bitter orange peel, lacking liquorice, lacking chuanxiong and angelica, lacking red peony root, and lacking rehmannia root respectively, and prepare negative sample solutions according to the method under (2.1.1).
[0080] (2.2) Chromatographic conditions
[0081] Chromatographic column: GL science C18 (4.6×250mm, 5μm);
[0082] Mobile phase: acetonitrile (A)-0.1% phosphoric acid aqueous solution (B);
[0083] Elution procedure: 0-4 min, 5%-6% A; 4-13 min, 6%-18% A; 13-18 min, 18%-19% A; 18-20 min, 19%-20% A; 20-30 min, 20%-21% A; 30-40 min, 21%-35% A; 40-50 min, 35%-50% A;
[0084] Flow rate: 1.2 mL / min;
[0085] Column temperature: 25°C;
[0086] Detection wavelength: 210nm;
[0087] Injection volume: 5 μL.
[0088] (3) Results of the methodological investigation on the fingerprint of Xuefu Zhuyu tablets
[0089] (3.1) Chromatographic peak identification results
[0090] Prepare samples according to item (2.1), analyze according to the chromatographic conditions in item (2.2), conduct specificity investigation, and identify chromatographic peaks.
[0091] Chromatogram see Figure 1 The results showed that the peak shapes of the chromatographic peaks of each reference substance were good. By comparing with the chromatograms of the negative test sample and the reference substance, 8 components were identified. The chromatographic peak of naringin in the chromatogram had a good peak shape, a high peak height, a large peak area, and a medium retention time, so naringin was selected as the reference peak.
[0092] (3.2) Precision investigation
[0093] Take a sample of Xuefu Zhuyu Tablets, prepare the test solution according to the method under (2.1.1), and inject the sample 6 times continuously according to the chromatographic conditions under (2.2), record the relative peak area of the common peak, and calculate the RSD.
[0094] Taking naringin as the reference peak, the relative peak area RSD of the common peak was calculated. The results showed that RSD was less than 3%, and the precision of this method was good. The precision investigation results are shown in Table 1.
[0095] Table 1: Precision test results
[0096]
[0097] (3.3) Repeatability study
[0098] Take a sample of Xuefu Zhuyu Tablets and prepare 6 test sample solutions in parallel according to the preparation method under (2.1.1). Inject the samples according to the chromatographic conditions under (2.2), record the relative peak area of the common peak, and calculate the RSD.
[0099] Taking naringin as the reference peak, the relative peak area and RSD of the common peak were calculated. The results showed that RSD was less than 3%. The repeatability of this method was good. The repeatability test results are shown in Table 2.
[0100] Table 2: Repeatability test results
[0101]
[0102] (3.4) Stability study
[0103] Take a sample of Xuefu Zhuyu Tablets, prepare the test solution according to the method under (2.1.1), and analyze the sample at 0, 2, 4, 8, 12, and 24 h according to the chromatographic conditions under (2.2), record the relative peak area and relative retention time of the common peak, and calculate the RSD.
[0104] Taking naringin as the reference peak, the relative peak area and RSD of the common peak were calculated. The results showed that RSD was less than 3%, and the stability of the test solution was good within 24 hours. The stability test results are shown in Table 3.
[0105] Table 3: Stability test results
[0106]
[0107]
[0108] (4) Establishment of fingerprint
[0109] Take 11 batches of Xuefu Zhuyu Tablets, prepare the test solution according to the method under (2.1.1), and analyze the samples according to the chromatographic conditions under (2.2). Import the chromatograms of the 11 batches of samples into the Chinese Medicine Fingerprint Software (2012A Edition) for data analysis, set the S1 sample as the reference spectrum, use multi-point correction to generate the fingerprint spectrum, determine the common peaks, and calculate the similarity of each batch of Xuefu Zhuyu Tablets samples.
[0110] See also Figure 2 , the Chinese medicine chromatographic fingerprint similarity evaluation system 2012A (Chinese Pharmacopoeia Committee) was used to generate the fingerprint. Figure 2 The 11 batches of Xuefu Zhuyu tablets mainly included 16 common peaks. Figure 3 , 8 designated peaks are shown Figure 4 , in this Figure 4 In , the specified peaks include:
[0111] Peak 1, with an average relative retention time of 0.24, represents rehmannia glutinosa glycoside D, which is mainly derived from the medicinal material Rehmannia glutinosa;
[0112] Peak 2, with an average relative retention time of 0.52, represents amygdalin, which is mainly derived from the medicinal raw material peach kernel;
[0113] Peak 3, with an average relative retention time of 0.64, represents paeoniflorin, which is mainly derived from the medicinal material red peony root;
[0114] Peak 4, with an average relative retention time of 0.79, represents liquiritin, which is mainly derived from the medicinal raw material licorice;
[0115] Peak 5, with an average relative retention time of 0.82, represents ferulic acid, which is mainly derived from the medicinal raw materials Angelica sinensis and Chuanxiong;
[0116] Peak 6, with an average relative retention time of 1.00; Peak 6 is used as the reference peak to calculate the relative retention time, representing naringin, which is mainly derived from the medicinal raw material Fructus Aurantii Immaturus;
[0117] Peak 7, with an average relative retention time of 1.04, represents hesperidin, which is mainly derived from the medicinal material Fructus Aurantii Immaturus;
[0118] Peak 8, with an average relative retention time of 1.13, represents neohesperidin, which is mainly derived from the medicinal material Fructus Aurantii Immaturus.
[0119] At the same time, the fingerprint similarity of 11 batches of Xuefu Zhuyu tablets was analyzed, and the experimental results are shown in Table 4:
[0120] Table 4: Similarity of fingerprints of Xuefu Zhuyu tablets
[0121]
[0122] (5) Cluster analysis and principal component analysis
[0123] The common peak areas of 11 batches of Xuefu Zhuyu tablets were clustered using SPSS software using the Euclidean distance square and average linkage method. SIMCA was used to establish the common peak area data matrix of 11 batches of Xuefu Zhuyu tablets, and the common peak area was used as a feature for principal component analysis.
[0124] IBM SPSS Statistics 25 software was used to analyze the 16 common peak areas ( Figure 2 ), cluster analysis was performed, and the results are shown in Figure 5 . The cluster analysis results show that the samples of Xuefu Zhuyu Tablets can be divided into two categories: Ⅰ (S3, S9, S7, S4, S8, S6, S10, S5), Ⅱ (S2, S11, S1). Among them, S3, S9, S7, S4 are clustered into one category and then clustered into one category with S8, indicating that Xuefu Zhuyu Tablets S3, S9, S7, S4, S8 have a certain unity. In category Ⅰ, S3, S9, S7, S4, S8 are clustered into one category and clustered into one category with S6, S10, S5, indicating that there are certain differences in the same category of samples. Similarly, S2 and S11 are clustered into one category alone and clustered with S1 to form category Ⅱ. There is a certain unity and difference between them.
[0125] Example 2: Investigation of chromatographic conditions
[0126] (1) Detection wavelength investigation
[0127] According to the chromatographic conditions under item (2.2) of Example 1, 5 μL of the test solution was injected, and the chromatograms at wavelengths of 200 nm, 210 nm, 254 nm, 270 nm, 300 nm, 367 nm, and 403 nm were analyzed using a DAD detector, and a 3D spectrum was recorded.
[0128] DAD 3D scanning chromatogram Figure 6 The results show that when the detection wavelength is 210nm, the chromatographic peak response value of each index component is higher, the chromatographic peak information is richer, and it can more comprehensively reflect the ultraviolet absorption of the chromatographic peaks of each component of Xuefu Zhuyu Tablets. At the same time, under the gradient elution procedure of the present technical solution, rapid and accurate detection of multiple components can be achieved at the single wavelength of 210nm.
[0129] (2) Column temperature investigation
[0130] According to the chromatographic conditions under (2.2) of Example 1, 5 μL of the test solution was injected and different column temperatures of 25°C, 30°C, and 35°C were investigated. The chromatogram was recorded. Figure 7 .
[0131] Column temperature investigation chromatogram see Figure 7(A: column temperature 25℃; B: column temperature 30℃; C: column temperature 35℃). The results show that the separation effect of each component is better at a column temperature of 25℃. Under the condition of a column temperature of 25℃, the separation degrees between the 8 characteristic peaks and adjacent peaks are all greater than ≥1.5, basically achieving baseline separation.
[0132] (3) Flow rate investigation
[0133] According to the chromatographic conditions under item (2.2) of Example 1, 5 μL of the test solution was injected, and different flow rates of 0.8 mL / min, 1.0 mL / min, and 1.2 mL / min were examined, and the chromatogram was recorded.
[0134] Flow rate investigation chromatogram see Figure 8 (A: flow rate 0.8mL / min; B: flow rate 1.0mL / min; C: flow rate 1.2mL / min). The results show that the separation effect of each component is better at 1.2mL / min, and the separation degree between each peak is better.
[0135] Example 3: Investigation of the preparation method of the test solution
[0136] (1) Investigation of extraction solvents
[0137] Take Xuefu Zhuyu tablets, scrape off the film coating and grind into fine powder. Take 0.5 g of the powder respectively, weigh accurately, add 50% methanol, 75% methanol and 50 mL of methanol respectively, prepare the solution according to the preparation method of the test sample under (2.1.1) of Example 1, inject the sample according to the chromatographic conditions under (2.2) of Example 1, and record the chromatogram.
[0138] The chromatogram of the extraction solvent investigation results is shown in Fig. 9 (A: 50% methanol; B: 75% methanol; C: 100% methanol), the results show that: after 75% methanol extraction, the total peak area is 4111.1mAU*min, after 50% methanol extraction, the total peak area is 4059.7mAU*min, after 100% methanol extraction, the total peak area is 3897.3mAU*min. It can be concluded that: after 75% methanol extraction, the total peak area is greater than that after 50% methanol and methanol extraction, and 75% methanol is preferably used as the extraction solvent.
[0139] (2) Investigation of extraction methods
[0140] Take Xuefu Zhuyu tablets, scrape off the film coating and grind into fine powder. Take 0.5 g of powder respectively, weigh accurately, add 75% methanol accurately, extract by ultrasound (power 300 W, frequency 40 kHz) and reflux extraction for 40 min respectively, prepare the solution according to the preparation method of the test sample under (2.1.1) of Example 1, inject the sample according to the chromatographic conditions under (2.2) of Example 1, and record the chromatogram.
[0141] The chromatogram of the extraction method is shown in Fig.10 (A: ultrasonic extraction; B: reflux extraction). The results showed that the common peak areas of ultrasonic extraction and reflux extraction were not much different, so ultrasonic extraction was determined to be the extraction method.
[0142] (3) Extraction time investigation
[0143] Take Xuefu Zhuyu tablets, scrape off the film coating and grind into fine powder. Take 0.5 g of the powder respectively, weigh accurately, and add 50 mL of 75% methanol according to the preparation method of the test sample under (2.1.1) of Example 1, and ultrasonicate for 20 min, 40 min, and 60 min respectively. According to the chromatographic conditions under (2.2) of Example 1, inject the sample and record the chromatogram.
[0144] Extraction time investigation chromatogram see Fig.11 (A: extraction time is 20 minutes; B: extraction time is 40 minutes; C: extraction time is 60 minutes). The results show that when the extraction time is 40 minutes, the total peak area has reached the maximum, and the extraction is relatively complete at this time.
[0145] (4) Sample volume investigation
[0146] The test sample solution was prepared according to the test sample preparation method under (2.1.1) of Example 1. According to the chromatographic conditions under (2.2) of Example 1, 5 μL, 10 μL, 15 μL, and 20 μL were injected respectively, and the chromatogram was recorded.
[0147] The chromatogram of injection volume inspection is shown in Fig.12 (A: injection volume is 5μL; B: injection volume is 10μL; C: injection volume is 15μL; D: injection volume is 20μL). The results show that when the injection volume is 5μL, the baseline of the chromatogram is relatively stable and the separation of each chromatographic peak is better.
[0148] Comparative Example 1
[0149] The prior art has attempted to evaluate Xuefu Zhuyu Tablets by HPLC fingerprint, see the document "Ma Mengge, Research on Quality Control of Xuefu Zhuyu Tablets Based on HPLC Fingerprint and One-Test-Multiple-Evaluation Method, Chinese Herbal Medicine, 2021, DOI: 10.7501 / j.issn.0253-2670.2021.22.010". The prior art and the present application are both about the fingerprint establishment method of Xuefu Zhuyu Tablets (Xuefu Zhuyu Tablets, abbreviated as XZT). Compared with the technical solution of the present application, the advantages of the technical solution of the present application include but are not limited to:
[0150] In the technical scheme of the existing technology (Ma Mengge et al.), HPLC identification and attribution are limited to amygdalin, paeoniflorin, naringin, hesperidin, ferulic acid, and neohesperidin. It can only quantitatively evaluate the effective ingredients of four medicinal materials in the preparation, namely, peach kernel, red peony root, bitter orange peel, and angelica sinensis, and its evaluation index is not comprehensive. On the basis of this existing technology (Ma Mengge, Research on the quality control of Xuefu Zhuyu tablets based on HPLC fingerprint and one-test-multiple-evaluation method, Chinese Herbal Medicine, 2021, DOI: 10.7501 / j.issn.0253-2670.2021.22.010), how to establish a method for more comprehensive evaluation of the quality of the drug preparation (Xuefu Zhuyu tablets) is one of the technical problems that need to be solved at present.
[0151] After this technical solution conducted a comparative study of multiple batches of Xuefu Zhuyu Tablets and further improved the detection method, the technical solution finally identified and attributed rehmannia glutinosa and liquiritin in addition to the 6 ingredients in the document. The rehmannia glutinosa and liquiritin are derived from the medicinal materials Rehmannia glutinosa and Licorice, respectively. In the HPLC fingerprint detection, the technical solution of this application can include more detection targets and achieve a more comprehensive evaluation of the quality of medicinal materials. The technical solution of the prior art (Ma Mengge et al.) does not provide a method for connecting rehmannia glutinosa and liquiritin to the other 6 ingredients for simultaneous detection.
[0152] In addition, in the technical solution of the prior art (Ma Mengge et al.), it is not possible to effectively detect the peak of liquiritin, and it is difficult to detect this characteristic component, so it is impossible to effectively control the quality of the medicinal raw material licorice. However, using the detection method of this solution, the peak of liquiritin (designated peak 4) has a good peak effect, and can form a good separation degree with the nearby chromatographic peak of ferulic acid (designated peak 5). The detection results of the prior art can be seen in detail. Fig.13 This figure is excerpted from the literature "Study on the quality control of Xuefu Zhuyu tablets based on HPLC fingerprint and one-test-multiple-evaluation method" Figure 1 XZT sample. In the HPLC test results ( Fig.13 ), no obvious chromatographic peak of liquiritin was found, so the detection method in the prior art has certain defects.
[0153] The above is only an embodiment of the present invention, and the common knowledge such as the known specific technical solutions and / or characteristics in the solution is not described in detail here. It should be pointed out that for those skilled in the art, without departing from the technical solution of the present invention, several modifications and improvements can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.
Claims
1. A method for establishing a fingerprint spectrum of a Xuefu Zhuyu composition, Features: The method includes the following steps: S1: using methanol to dissolve the Xuefu Zhuyu composition, and obtaining a test solution after ultrasonic treatment and filtration; S2: performing high performance liquid chromatography on the test sample solution to obtain a chromatogram of the test sample; integrating the chromatograms of several test samples to generate a fingerprint of the Xuefu Zhuyu composition.
2. The method for establishing the fingerprint of the Xuefu Zhuyu composition according to claim 1, Features: In S2, the fingerprint spectrum includes 8 designated peaks, the first designated peak represents rehmannoside D, the second designated peak represents amygdalin, the third designated peak represents paeoniflorin, the fourth designated peak represents liquiritigenin, the fifth designated peak represents ferulic acid, the sixth designated peak represents naringin, the seventh designated peak represents hesperidin, and the eighth designated peak represents neohesperidin.
3. The method for establishing the fingerprint spectrum of the Xuefu Zhuyu composition according to claim 2, Features: Rehmannia glutinosa D is derived from the medicinal material Rehmannia glutinosa; amygdalin is derived from the medicinal material peach kernel; paeoniflorin is derived from the medicinal material red peony root; liquiritigenin is derived from the medicinal material liquorice; ferulic acid is derived from the medicinal materials Angelica sinensis and Chuanxiong; naringin is derived from the medicinal material Citrus aurantium; hesperidin is derived from the medicinal material Citrus aurantium; neohesperidin is derived from the medicinal material Citrus aurantium; Taking the 6th designated peak as the reference peak, the relative retention time of the 1st designated peak is 0.24±10%; the relative retention time of the 2nd designated peak is 0.52±10%; the relative retention time of the 3rd designated peak is 0.64±10%; the relative retention time of the 4th designated peak is 0.79±10%; the relative retention time of the 5th designated peak is 0.82±10%; the relative retention time of the 6th designated peak is 1.00; the relative retention time of the 7th designated peak is 1.04±10%; the relative retention time of the 8th designated peak is 1.13±10%; Preferably, the relative retention time of the first designated peak is 0.24±5%; the relative retention time of the second designated peak is 0.52±5%; the relative retention time of the third designated peak is 0.64±5%; the relative retention time of the fourth designated peak is 0.79±5%; the relative retention time of the fifth designated peak is 0.82±5%; the relative retention time of the sixth designated peak is 1.00; the relative retention time of the seventh designated peak is 1.04±5%; the relative retention time of the eighth designated peak is 1.13±5%; More preferably, the relative retention time of the first designated peak is 0.24±2%; the relative retention time of the second designated peak is 0.52±2%; the relative retention time of the third designated peak is 0.64±2%; the relative retention time of the fourth designated peak is 0.79±2%; the relative retention time of the fifth designated peak is 0.82±2%; the relative retention time of the sixth designated peak is 1.00; the relative retention time of the seventh designated peak is 1.04±2%; and the relative retention time of the eighth designated peak is 1.13±2%.
4. The method for establishing the fingerprint spectrum of the Xuefu Zhuyu composition according to claim 1, Features: In S2, the conditions for HPLC detection are: Chromatographic column: octadecyl bonded silica gel chromatographic column; Mobile phase: acetonitrile as mobile phase A, 0.1% phosphoric acid aqueous solution as mobile phase B; gradient elution was used; Flow rate: 0.8~1.2mL / min; Column temperature: 25-35°C; Detection wavelength: 200~403nm; Injection volume: 5~20μL.
5. The method for establishing the fingerprint spectrum of the Xuefu Zhuyu composition according to claim 4, Features: In S2, the elution program is: 0-4min, 5%-6% mobile phase A; 4-13 min, 6%-18% mobile phase A; 13-18 min, 18%-19% mobile phase A; 18-20 min, 19%-20% mobile phase A; 20-30 min, 20%-21% mobile phase A; 30-40 min, 21%-35% mobile phase A; 40-50 min, 35%-50% mobile phase A.
6. The method for establishing the fingerprint spectrum of the Xuefu Zhuyu composition according to claim 5, Features: In S2, the chromatographic column is a GL science C18 chromatographic column with dimensions of 4.6×250 mm and a particle size of 5 μm.
7. The method for establishing the fingerprint spectrum of the Xuefu Zhuyu composition according to claim 1, Features: In S1, the volume percentage of methanol is 50% to 100%; the Xuefu Zhuyu composition is ground and mixed with methanol, and the amount ratio of the Xuefu Zhuyu composition to methanol is (0.25g:50mL) to (0.75g:50mL); the parameter conditions of ultrasonic treatment are: power 100-300W, frequency 25-100kHz, time 20-60 minutes; the pore size of the microporous filter membrane used for filtration is 0.45μm; Preferably, the ultrasonic treatment parameters are: power 300 W, frequency 40 kHz, and time 40 minutes.
8. The standard fingerprint of the Xuefu Zhuyu composition obtained by the method for establishing the fingerprint of the Xuefu Zhuyu composition according to any one of claims 1 to 7.
9. Application of the standard fingerprint of the Xuefu Zhuyu composition according to claim 8 in the quality detection of drugs containing the Xuefu Zhuyu composition.
10. Application of the standard fingerprint of the Xuefu Zhuyu composition according to claim 9 in the quality detection of drugs containing the Xuefu Zhuyu composition, It is characterized in that In parts by weight, the raw materials of the Xuefu Zhuyu composition include: 25-30 parts of bupleurum, 75-90 parts of angelica, 75-90 parts of rehmannia, 50-60 parts of red peony root, 75-90 parts of safflower, 105-120 parts of peach kernel, 50-60 parts of Citrus aurantium, 25-30 parts of licorice, 35-45 parts of chuanxiong, 75-90 parts of Achyranthes bidentata, and 35-45 parts of Platycodon. Preferably, in parts by weight, the raw materials of the Xuefu Zhuyu composition include: 29.9 parts of bupleurum, 89.8 parts of angelica, 89.9 parts of rehmannia, 59.9 parts of red peony root, 89.9 parts of safflower, 119.8 parts of peach kernel, 59.9 parts of Citrus aurantium, 29.9 parts of liquorice, 44.9 parts of ligusticum, 89.9 parts of Achyranthes bidentata and 44.9 parts of Platycodon. Preferably, the peach kernel is fried peach kernel, and the Citrus aurantium is fried Citrus aurantium with bran.
